SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,165,441,614 |
| Positions | 98 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ASCENDIS PHARMA A/S | ASND | ORD SHS | $62,191,369 | 233,171 |
| AXSOME THERAPEUTICS INC. | AXSM | COM | $53,750,513 | 219,596 |
| ELI LILLY & CO | LLY | COM | $47,087,223 | 39,258 |
| JAZZ PHARMACEUTICALS PLC | JAZZ | SHS USD | $38,740,265 | 160,768 |
| HUMANA INC | HUM | COM | $37,487,638 | 94,375 |
| UNITEDHEALTH GROUP INC | UNH | COM | $36,690,154 | 88,276 |
| NEUROCRINE BIOSCIENCES INC | NBIX | COM | $35,966,549 | 213,407 |
| INHIBRX BIOSCIENCES INC | INBX | COM | $29,219,479 | 308,385 |
| UNITED THERAPEUTICS CORP DEL | UTHR | COM | $27,086,624 | 49,991 |
| REVOLUTION MEDICINES INC | RVMD | COM | $26,822,616 | 143,222 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.